MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

227.35
+25.26
+12.50%
After Hours: 225.64 -1.71 -0.75% 19:59 04/16 EDT
OPEN
201.71
PREV CLOSE
202.09
HIGH
228.10
LOW
200.50
VOLUME
4.51M
TURNOVER
--
52 WEEK HIGH
331.68
52 WEEK LOW
16.41
MARKET CAP
16.79B
P/E (TTM)
-33.5038
1D
5D
1M
3M
1Y
5Y
Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
Yahoo Finance UK · 1d ago
8-K: NOVAVAX INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Fauci Says Clinical Trials Are Already Looking At Possible COVID-19 Vaccine Booster Shots
-Reuters 
Reuters  · 2d ago
Buy Novavax Because It Could Be About to Score With Covid-19 Vaccine, Analyst Says.
CFRA analyst Sel Hardy began coverage of the stock with a Strong Buy rating, saying she expects emergency-use authorization to be granted quickly.
Barrons.com · 2d ago
Malaria Vaccine Market Research Report by Type, by Agent, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19
GlobeNewswire · 2d ago
U.S. Vaccine Market by Type, Stage, End-User
Apr 16, 2021 (Market Insight Reports) -- U.S. Vaccines Market Vaccination of animals is being used to prevent illness in the animals as well as disease...
Market Insight Reports · 2d ago
Indian vaccine maker Serum Institute appeals to Biden to lift embargo on raw material exports
reuters.com · 2d ago
Global Vaccine Particulate Adjuvants Market Size 2021 Research Reports, Industry Share, In-Depth Qualitative Insights, Growth Opportunity, Regional Analysis And Forecast To 2024
The Express Wire · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVAX. Analyze the recent business situations of Novavax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVAX stock price target is 300.75 with a high estimate of 365.00 and a low estimate of 211.00.
EPS
Institutional Holdings
Institutions: 401
Institutional Holdings: 42.57M
% Owned: 57.64%
Shares Outstanding: 73.86M
TypeInstitutionsShares
Increased
114
8.84M
New
97
1.71M
Decreased
83
2.41M
Sold Out
54
1.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
James Young
President/Chief Executive Officer/Director
Stanley Erck
Chief Financial Officer/Executive Vice President
John Trizzino
Corporate Executive
Gregory Glenn
Chief Operating Officer/Executive Vice President
Rick Crowley
Chief Human Resource Officer/Executive Vice President
Jill Hoyt
Executive Vice President/Chief Compliance Officer
Troy Morgan
Executive Vice President
John Herrmann
Vice President
Kathleen Callahan
Vice President
Susan Hensley
Executive Vice President
Ben Machielse
Senior Vice President/Director of Sales
Frank Czworka
Senior Vice President/Director of Investor Relations
Silvia Taylor
Senior Vice President
Madelyn Caltabiano
Senior Vice President
Filip Dubovsky
Senior Vice President
Jody Lichaa
Senior Vice President
Brian Rosen
Senior Vice President
Gale Smith
Senior Vice President
Henrietta Ukwu
Senior Vice President
Brian Webb
Director
Gregg Alton
Director
Rajiv Modi
Independent Director
Richard Douglas
Independent Director
Gary Evans
Independent Director
Rachel King
Independent Director
Margaret McGlynn
Independent Director
Michael McManus
Independent Director
David Mott
No Data
  • All
  • Financials
  • Insiders
More
About NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.